Deutsche Bank Defends Gilead Sciences (GILD) on Sector Setback
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $130.46 -0.72%
Rating Summary:
37 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 22 | New: 8
Rating Summary:
37 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 22 | New: 8
Join SI Premium – FREE
Deutsche Bank commented on Gilead Sciences (NASDAQ: GILD) following news in the sector from Idenix Pharmaceuticals Inc. (Nasdaq: IDIX), which said the FDA placed hepatitis C drug IDX184 on partial clinical hold due to a serious cardiac-related adverse event.
The firm said they spoke with GILD management and the company believes the concerns with IDX184 are drug-specific, not on entire nuke class. GILD said they have not been contacted by the FDA.
The analyst comments: "Notably, GS-7977 has been dosed in over 1000 patients for 12 weeks. Recall, IDX 184 had only been tested in 67 patients for 2 weeks. Furthermore, GS-7977 has already successfully completed a thorough QTC study. This provides us with significant comfort that GS-7977 does not have cardiac issues. From speaking with different thought leaders in the HCV space, it is our sense that the FDA becomes more comfortable when >200 patients have been dosed. Gilead reiterated that it paid $11B for GS-7977 due to its significant safety database."
The firm reiterated their Buy rating and price target of $68.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.97 yesterday.
The firm said they spoke with GILD management and the company believes the concerns with IDX184 are drug-specific, not on entire nuke class. GILD said they have not been contacted by the FDA.
The analyst comments: "Notably, GS-7977 has been dosed in over 1000 patients for 12 weeks. Recall, IDX 184 had only been tested in 67 patients for 2 weeks. Furthermore, GS-7977 has already successfully completed a thorough QTC study. This provides us with significant comfort that GS-7977 does not have cardiac issues. From speaking with different thought leaders in the HCV space, it is our sense that the FDA becomes more comfortable when >200 patients have been dosed. Gilead reiterated that it paid $11B for GS-7977 due to its significant safety database."
The firm reiterated their Buy rating and price target of $68.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lucid Group resumes trading, down only 23%
- TriCo Bancshares (TCBK) PT Raised to $66 at DA Davidson as Merger with First Hawaiian Bank Announced
- Tractor Supply Company (TSCO) PT Lowered to $33 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
